Stay updated with breaking news from Tyme Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) major shareholder Michael Demurjian sold 53,097 shares of the company’s stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $0.25, for a total value of $13,274.25. Following the completion of the sale, the insider now owns 23,355,749 shares of the […]
25.05.2022 - - $84.0 million in cash and marketable securities as of March 31, 2022 -BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) - TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer ...
Tyme-10k_20220331.htm Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | May 25, 2022
Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) major shareholder Michael Demurjian sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 19th. The shares were sold at an average price of $0.32, for a total value of $12,800.00. Following the completion of the transaction, the insider now directly owns 23,648,846 […]
Mr. Dickey brings over 25 years of experience as a CFO and COO in private, public, and revenue stage companies with deep capital markets and business development transactional expertise across life science